Search research articles
Contact Us
Filters
Showing results (191-200 of 323) with videos related to
Page
of 33
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2016
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
Filippo Pietrantonio, Claudio Vernieri, Giulia Siravegna, et al.
JCO Precision Oncology
|
May 11, 2022
Negative Ultraselection of Patients With <i>RAS</i>/<i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy
Giovanni Randon, Giulia Maddalena, Marco Maria Germani, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 4, 2023
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV
Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini, et al.
The New England Journal of Medicine
|
October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C
Marwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
British Journal of Cancer
|
March 14, 2018
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
Chiara Cremolini, Massimo Milione, Federica Marmorino, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2021
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Filippo Pietrantonio, Sara Lonardi, Francesca Corti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, et al.
ESMO Open
|
April 10, 2019
Benefit from anti-EGFRs in <i>RAS</i> and <i>BRAF</i> wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
Chiara Cremolini, Matteo Benelli, Elisa Fontana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2016
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest
Chiara Cremolini, Mariaelena Casagrande, Fotios Loupakis, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
December 29, 2016
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world
Valentina Fanotto, Stefano Cordio, Giulia Pasquini, et al.
Page
of 33
Search research articles
Search
Showing results (191-200 of 323) with videos related to
Sort By:
Page
of 33
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2016
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
Filippo Pietrantonio, Claudio Vernieri, Giulia Siravegna, et al.
JCO Precision Oncology
|
May 11, 2022
Negative Ultraselection of Patients With <i>RAS</i>/<i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy
Giovanni Randon, Giulia Maddalena, Marco Maria Germani, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 4, 2023
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV
Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini, et al.
The New England Journal of Medicine
|
October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C
Marwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
British Journal of Cancer
|
March 14, 2018
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
Chiara Cremolini, Massimo Milione, Federica Marmorino, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2021
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Filippo Pietrantonio, Sara Lonardi, Francesca Corti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, et al.
ESMO Open
|
April 10, 2019
Benefit from anti-EGFRs in <i>RAS</i> and <i>BRAF</i> wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
Chiara Cremolini, Matteo Benelli, Elisa Fontana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2016
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest
Chiara Cremolini, Mariaelena Casagrande, Fotios Loupakis, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
December 29, 2016
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world
Valentina Fanotto, Stefano Cordio, Giulia Pasquini, et al.
Page
of 33